5hcc - Revision history

OCA at 07:30, 9 August 2023

OCA — Wed, 09 Aug 2023 07:30:31 GMT

←Older revision		Revision as of 07:30, 9 August 2023
Line 3:		Line 3:
	<StructureSection load='5hcc' size='340' side='right'caption='[[5hcc]], [[Resolution\|resolution]] 2.59Å' scene=''>		<StructureSection load='5hcc' size='340' side='right'caption='[[5hcc]], [[Resolution\|resolution]] 2.59Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5hcc]] is a 4 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Argasid_tick Argasid tick~~], [~~http~~://en.wikipedia.org/wiki/~~Deran Deran~~] and [~~http~~://en.wikipedia.org/wiki/~~Homo_sapiens Homo sapiens~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HCC OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5HCC FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5hcc]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Dermacentor_andersoni Dermacentor andersoni], [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Ornithodoros_moubata Ornithodoros moubata]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HCC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5HCC FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=DIO:1,4-DIETHYLENE+DIOXIDE'>DIO</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.59Å</td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CI ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=6938 Argasid tick])~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=DIO:1,4-DIETHYLENE+DIOXIDE'>DIO</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5hcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hcc OCA], [~~http~~://pdbe.org/5hcc PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5hcc RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5hcc PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5hcc ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5hcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hcc OCA], [https://pdbe.org/5hcc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5hcc RCSB], [https://www.ebi.ac.uk/pdbsum/5hcc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5hcc ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN]] Defects in C5 are the cause of complement component 5 deficiency (C5D) [MIM:[~~http~~://omim.org/entry/609536 609536]]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Note=An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705).	+	[https://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN] Defects in C5 are the cause of complement component 5 deficiency (C5D) [MIM:[https://omim.org/entry/609536 609536]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Note=An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705).
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN]] Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis).	+	[https://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN] Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis).
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 28:		Line 28:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Argasid tick]]~~	+	[[Category: Dermacentor andersoni]]
-	~~[[Category: Deran~~]]	+
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Johnson, S~~]]	+	[[Category: Ornithodoros moubata]]
-	[[Category: ~~Jore, M M]]~~	+	[[Category: Johnson S]]
-	~~[[Category: Lea,~~ S M]]	+	[[Category: Jore MM]]
-	[[Category: ~~Complement~~]]	+	[[Category: Lea SM]]
-	[[Category: ~~Immune system]]~~	+
-	~~[[Category: Inflammation]]~~	+
-	~~[[Category: Inhibitor]]~~	+
-	~~[[Category: Tick~~]]	+

OCA at 06:59, 20 May 2020

OCA — Wed, 20 May 2020 06:59:40 GMT

←Older revision		Revision as of 06:59, 20 May 2020
Line 1:		Line 1:

	==Ternary complex of human Complement C5 with Ornithodoros moubata OmCI and Dermacentor andersoni RaCI3.==		==Ternary complex of human Complement C5 with Ornithodoros moubata OmCI and Dermacentor andersoni RaCI3.==
-	<StructureSection load='5hcc' size='340' side='right' caption='[[5hcc]], [[Resolution\|resolution]] 2.59Å' scene=''>	+	<StructureSection load='5hcc' size='340' side='right'caption='[[5hcc]], [[Resolution\|resolution]] 2.59Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5hcc]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/ ] and [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HCC OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5HCC FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5hcc]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Argasid_tick Argasid tick], [http://en.wikipedia.org/wiki/Deran Deran] and [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HCC OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5HCC FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=DIO:1,4-DIETHYLENE+DIOXIDE'>DIO</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=DIO:1,4-DIETHYLENE+DIOXIDE'>DIO</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5hcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hcc OCA], [http://pdbe.org/5hcc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hcc RCSB], [http://www.ebi.ac.uk/pdbsum/5hcc PDBsum]</span></td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CI ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=6938 Argasid tick])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5hcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hcc OCA], [http://pdbe.org/5hcc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hcc RCSB], [http://www.ebi.ac.uk/pdbsum/5hcc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5hcc ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 5hcc" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5hcc" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Complement C5 3D structures\|Complement C5 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Argasid tick]]
		+	[[Category: Deran]]
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
	[[Category: Johnson, S]]		[[Category: Johnson, S]]
	[[Category: Jore, M M]]		[[Category: Jore, M M]]

OCA at 16:03, 10 May 2016

OCA — Tue, 10 May 2016 16:03:48 GMT

←Older revision		Revision as of 16:03, 10 May 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5hcc is ~~ON HOLD~~ ~~until Paper~~ Publication	+	==Ternary complex of human Complement C5 with Ornithodoros moubata OmCI and Dermacentor andersoni RaCI3.==
		+	<StructureSection load='5hcc' size='340' side='right' caption='[[5hcc]], [[Resolution\|resolution]] 2.59Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5hcc]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/ ] and [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HCC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5HCC FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=DIO:1,4-DIETHYLENE+DIOXIDE'>DIO</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5hcc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hcc OCA], [http://pdbe.org/5hcc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hcc RCSB], [http://www.ebi.ac.uk/pdbsum/5hcc PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN]] Defects in C5 are the cause of complement component 5 deficiency (C5D) [MIM:[http://omim.org/entry/609536 609536]]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Note=An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705).
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/CO5_HUMAN CO5_HUMAN]] Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis).
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Activation of complement C5 generates the potent anaphylatoxin C5a and leads to pathogen lysis, inflammation and cell damage. The therapeutic potential of C5 inhibition has been demonstrated by eculizumab, one of the world's most expensive drugs. However, the mechanism of C5 activation by C5 convertases remains elusive, thus limiting development of therapeutics. Here we identify and characterize a new protein family of tick-derived C5 inhibitors. Structures of C5 in complex with the new inhibitors, the phase I and phase II inhibitor OmCI, or an eculizumab Fab reveal three distinct binding sites on C5 that all prevent activation of C5. The positions of the inhibitor-binding sites and the ability of all three C5-inhibitor complexes to competitively inhibit the C5 convertase conflict with earlier steric-inhibition models, thus suggesting that a priming event is needed for activation.

-	~~Authors: Jore, M.M~~., ~~Johnson~~, S., ~~Lea~~, S.M.	+	Structural basis for therapeutic inhibition of complement C5.,Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, Elmlund H, Lea SM Nat Struct Mol Biol. 2016 May;23(5):378-86. doi: 10.1038/nsmb.3196. Epub 2016 Mar, 28. PMID:27018802<ref>PMID:27018802</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5hcc" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Johnson, S]]		[[Category: Johnson, S]]
-	[[Category: ~~Lea~~, S.M]]	+	[[Category: Jore, M M]]
-	[[Category: ~~Jore~~, M.M]]	+	[[Category: Lea, S M]]
		+	[[Category: Complement]]
		+	[[Category: Immune system]]
		+	[[Category: Inflammation]]
		+	[[Category: Inhibitor]]
		+	[[Category: Tick]]

OCA at 00:31, 28 January 2016

OCA — Thu, 28 Jan 2016 00:31:51 GMT

←Older revision		Revision as of 00:31, 28 January 2016
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5hcc is ON HOLD	+	The entry 5hcc is ON HOLD until Paper Publication

-	Authors: Jore, M.M, Johnson, S, Lea, S.M.	+	Authors: Jore, M.M., Johnson, S., Lea, S.M.

	Description:		Description:
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
-	[[Category: ~~Jore, M.M,~~ Johnson, S, Lea, S.M]]	+	[[Category: Johnson, S]]
		+	[[Category: Lea, S.M]]
		+	[[Category: Jore, M.M]]

OCA: Protected "5hcc" [edit=sysop:move=sysop]

OCA — Wed, 13 Jan 2016 18:48:30 GMT

Protected "5hcc" [edit=sysop:move=sysop]

←Older revision

Revision as of 18:48, 13 January 2016

OCA: New page: '''Unreleased structure''' The entry 5hcc is ON HOLD Authors: Jore, M.M, Johnson, S, Lea, S.M. Description: Category: Unreleased Structures [[Category: Jore, M.M, Johnson, S, Lea,...

OCA — Wed, 13 Jan 2016 18:48:28 GMT

New page: '''Unreleased structure''' The entry 5hcc is ON HOLD Authors: Jore, M.M, Johnson, S, Lea, S.M. Description: Category: Unreleased Structures [[Category: Jore, M.M, Johnson, S, Lea,...

New page

'''Unreleased structure'''

The entry 5hcc is ON HOLD

Authors: Jore, M.M, Johnson, S, Lea, S.M.

Description:
[[Category: Unreleased Structures]]
[[Category: Jore, M.M, Johnson, S, Lea, S.M]]